ArticleClinical kidney journal2026
The epidemiology of end-stage kidney failure in France: reason for hope?
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Many European countries have experienced a decrease in the incidence of kidney replacement therapy (KRT), from as far back as 2008 for some. However, in France, the incidence increased by +0.8% annually from 2005 to 2014. This study aimed to examine the recent trend in incidence of KRT in France and variations in different subgroups to understand the possible mechanisms involved. Methods: To estimate the trend in KRT incidence for the French population, we used data from the Renal Epidemiology Information Network (REIN) registry, which has been available and comprehensive since 2012 for all of France. We estimated time trends from 2012 to 2023 by using a Joinpoint regression model that provides the annual percentage change and its confidence interval. We also analyzed the data by patient subgroups (age, comorbidities, etc.) or treatment conditions (emergency initiation, preemptive kidney transplantation, etc.). Results: From 2012 to 2017, the number of new patients starting KRT increased annually by +2.7% in France, but the standardized incidence was stable. Since 2017, the number of new patients has been stable and the age- and sex-standardized incidence rate has decreased annually by 2.2%, likely due to the aging of the population. The reversal of the trend was particularly noticeable among older people and people with diabetes. Early mortality in people aged ≥75 years decreased significantly, which suggests that the most comorbid patients are now referred for conservative treatment. Even before the flat-rate payment system was introduced in 2019, more comprehensive and multidisciplinary care may have been developed for patients with stage 4-5 disease. Conclusion: In France, since 2017, the age- and sex-standardized KRT incidence rate decreased probably due to the combination of factors relating to changes in practices, the arrival of new treatments and changes in the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.